ITP: Biologic Beat Placebo, but Few Patients Improved ITP: Biologic Beat Placebo, but Few Patients Improved

Patients with chronic immune thrombocytopenia (ITP) fared better on intravenous efgartigimod (Vyvgart) than a placebo, but only 21.8% reached the primary endpoint of sustained platelet.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news